🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Primary Hyperoxaluria Type 1

A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) NCT07681271Phase 212 sites📍 El Paso📍 Sofia📍 Sofia Novartis Pharmaceuticals · Tests: LOU064, Placebo Prospective Research Rare Kidney Stones (ProRKS) NCT02780297n/a11 sites📍 Birmingham📍 Jacksonville📍 Chicago Mayo Clinic Monogenic Kidney Stone - Genetic Testing NCT03305835n/a1 site📍 Rochester Mayo Clinic Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France. NCT06225882n/a7 sites📍 Besançon📍 Bron📍 Lyon Hospices Civils de Lyon · Tests: Oxaluria evolution. Rare Kidney Stone Consortium Patient Registry NCT00588562n/a4 sites📍 Rochester📍 Rochester📍 New York Mayo Clinic Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1) NCT07776626Phase 11 site📍 Shanghai YolTech Therapeutics Co., Ltd · Tests: YOLT-203 Rare Kidney Stone Consortium Biobank NCT02026388n/a1 site📍 Rochester Mayo Clinic Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD NCT04580420Phase 218 sites📍 San Francisco📍 Boston📍 Rochester Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Tests: DCR-PHXC Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) NCT06511349EARLY Phase 11 site📍 Shanghai RenJi Hospital · Tests: YOLT-203 Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) NCT07587021Phase 24 sites📍 Birmingham📍 Aurora📍 St Louis YolTech Therapeutics Co., Ltd · Tests: YOLT-203, Placebo Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) NCT06839235Phase 1, Phase 27 sites📍 Rochester📍 Saint Paul📍 Lyon Arbor Biotechnologies · Tests: ABO-101 National Registry of Rare Kidney Diseases NCT06065852n/a1 site📍 Bristol UK Kidney Association
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy